STOCK TITAN
  1. Home
  2. Sec-filings
  3. KRYS
  4. [Form 4] Krystal Biotech, Inc. Insider Trading Activity

Krystal Biotech grants director options, RSUs

Krystal Biotech granted a director new stock options and restricted stock units that vest in 2027 as part of board compensation.

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Krystal Biotech, Inc. (symbol: KRYS) is the issuer of record for a Form 4 filing submitted to the SEC. Mazzacco Catherine reported acquisition or exercise transactions in this Form 4 filing.

Krystal Biotech, Inc. (KRYS) reported that director Catherine Mazzacco received equity awards on September 14, 2026. She was granted 1,187 stock options to buy common stock at $340.03 per share, expiring on September 13, 2036, and 471 restricted stock units. Both awards vest in full on September 14, 2027, subject to her continued service on the board and potential earlier vesting under the company’s Non-Employee Director Compensation Policy. No Rule 10b5-1 trading plan is reported for these awards.

Positive

  • None.

Negative

  • None.
Insider Mazzacco Catherine
Role Director
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) F1 1,187 $0.00 $0.00
Grant/Award Restricted Stock Units F2, F3 471 $0.00 $0.00
Holdings After Transaction: Stock Option (Right to Buy) — 1,187 contracts (Direct); Restricted Stock Units — 471 contracts (Direct)
Footnotes (3)
  1. F1. The stock options vest in full on September 14, 2027, subject to continued service on the Company's Board of Directors through such date and to earlier vesting in certain circumstances described in the Company's Non-Employee Director Compensation Policy as in effect on the date of grant.
  2. F2. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Company's common stock.
  3. F3. The RSUs vest in full on September 14, 2027, subject to continued service on the Company's Board of Directors through such date and to earlier vesting in certain circumstances described in the Company's Non-Employee Director Compensation Policy as in effect on the date of grant.
Stock options granted 1,187 options Director grant on September 14, 2026
Stock option exercise price $340.03 per share Exercise price for 1,187 options granted to a director
Stock option expiration September 13, 2036 Scheduled expiration date of the granted stock options
Restricted stock units granted 471 RSUs Director grant on September 14, 2026
Vesting date for awards September 14, 2027 Full vesting date for both options and RSUs, subject to continued board service
Options held after grant 1,187 options Director’s reported direct holdings in this option grant after the transaction
RSUs held after grant 471 RSUs Director’s reported direct holdings in this RSU grant after the transaction
Restricted Stock Units financial
"Each restricted stock unit ("RSU") represents a contingent right to receive one share"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Non-Employee Director Compensation Policy financial
"described in the Company's Non-Employee Director Compensation Policy as in effect"
vest in full financial
"The RSUs vest in full on September 14, 2027, subject to continued service"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did KRYS grant to director Catherine Mazzacco on September 14, 2026?
On September 14, 2026, Catherine Mazzacco received 1,187 stock options to buy Krystal Biotech common stock at $340.03 per share and 471 restricted stock units, all as direct holdings.

When do Catherine Mazzacco’s new KRYS stock options and RSUs vest?
Both the 1,187 stock options and 471 restricted stock units granted to Catherine Mazzacco vest in full on September 14, 2027, subject to her continued service on Krystal Biotech’s Board of Directors and certain earlier-vesting circumstances in the board compensation policy.

What is the exercise price and expiration date of Catherine Mazzacco’s new KRYS stock options?
The newly granted stock options allow Catherine Mazzacco to acquire Krystal Biotech common stock at an exercise price of $340.03 per share and are scheduled to expire on September 13, 2036, if not earlier exercised or forfeited under their terms.

How many KRYS restricted stock units did Catherine Mazzacco receive in this Form 4?
Catherine Mazzacco received 471 restricted stock units. Each unit represents a contingent right to receive one share of Krystal Biotech common stock, vesting in full on September 14, 2027, subject to continued board service and potential earlier vesting under the compensation policy.

Are Catherine Mazzacco’s KRYS equity awards granted under a Rule 10b5-1 trading plan?
No. The Form 4 indicates that these equity awards were not reported as made under a Rule 10b5-1 trading plan. They are described as grants subject to vesting conditions in Krystal Biotech’s Non-Employee Director Compensation Policy.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Mazzacco Catherine
(Last)(First)(Middle)
C/O KRYSTAL BIOTECH, INC.
2100 WHARTON STREET, SUITE 701
(Street)
PITTSBURGH PENNSYLVANIA 15203
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Krystal Biotech, Inc. [ KRYS ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
09/14/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$340.0309/14/2026A1,187 (1)09/13/2036Common Stock1,187$01,187D
Restricted Stock Units(2)09/14/2026A471 (3) (3)Common Stock471$0471D
Explanation of Responses:
1. The stock options vest in full on September 14, 2027, subject to continued service on the Company's Board of Directors through such date and to earlier vesting in certain circumstances described in the Company's Non-Employee Director Compensation Policy as in effect on the date of grant.
2. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Company's common stock.
3. The RSUs vest in full on September 14, 2027, subject to continued service on the Company's Board of Directors through such date and to earlier vesting in certain circumstances described in the Company's Non-Employee Director Compensation Policy as in effect on the date of grant.
Remarks:
/s/ Krish Krishnan, as attorney-in-fact for Catherine Mazzacco09/16/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

Keep reading

More on KRYS

Trending in the feed

Open the live feed